pdufa
.bio
Calendar
Decisions
Research
Home
›
Decisions
› NVO 2026-03-19
NVO
FDA decision
— Mar 19, 2026
✓ APPROVED
Novo Nordisk A/S — Wegovy HD · Obesity.
Run-up into the decision (T-120 → T+5)
PDUFA 3/19/26
$63.98
$36.66
10/2/25
Daily close, T-120 (10/2/25) through T+5. Run-up high $63.98 on 1/27/26, low $36.66 on 3/3/26 (T-120 to T-1). FDA decision 3/19/26. Historical price action, not a forecast.
Key facts
FDA decision date
2026-03-19
Outcome
Approved
Drug / candidate
Wegovy HD
Company
Novo Nordisk A/S
120-day run-up (T-120→T-1)
-33.2%
Not affiliated with or endorsed by the FDA.
Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio